Feature | April 08, 2014

SCAI Issues List of Tests, Treatments to Avoid as Part of Choosing Wisely Campaign

SCAI’s list will help patients and physicians work together to determine the best course of care

SCAI ACC.14 Choosing Wisely Campaign Tests Treatments to Avoid Cath Lab

April 8, 2014 — The Society for Cardiovascular Angiography & Interventions (SCAI) issued a list of five specific, evidence-based recommendations that should be avoided in the care of patients who have, or are at risk for, cardiovascular disease. SCAI’s list was developed as part of Choosing Wisely, an initiative of the ABIM Foundation, to help physicians and patients make wise decisions together about the most appropriate care based on individual situations.

SCAI’s list includes the following five recommendations:

• Avoid routine stress testing after percutaneous coronary intervention (PCI) without specific clinical indications.

• Avoid coronary angiography in post–coronary artery bypass graft (CABG) and post-PCI patients who are asymptomatic, or who have normal or mildly abnormal stress tests and stable symptoms not limiting quality of life.

• Avoid coronary angiography for risk assessment in patients with stable ischemic heart disease who are unwilling to undergo revascularization or who are not candidates for revascularization based on co-morbidities or individual preferences.

• Avoid coronary angiography to assess risk in asymptomatic patients with no evidence of ischemia or other abnormalities on adequate non-invasive testing.\

• Avoid PCI in asymptomatic patients with stable ischemic heart disease without the demonstration of ischemia on adequate stress testing or with abnormal fractional flow reserve testing.

“We believe this list will spur conversations between heart patients and their physicians to make wise decisions about care based on their individual situation,” said James C. Blankenship, M.D., FSCAI, 2013-14 vice president of SCAI. “Our goal is to improve care for the patient and eliminate unnecessary tests and procedures.”

SCAI’s list is based on guidelines and appropriate use criteria developed by SCAI, the American College of Cardiology (ACC), American Heart Association (AHA) and other professional societies. All of the tests and procedures on SCAI’s list have been deemed to be “inappropriate” or “rarely appropriate,” according to the latest appropriate use criteria, or are “not recommended,” according to the most current professional guidelines. SCAI selected these items because appropriate use criteria and guidelines have been carefully vetted, adjudicated and agreed upon by experts from many societies.

“SCAI has shown tremendous leadership by releasing its list of tests and procedures they say are commonly done in invasive/interventional cardiology, but aren’t always necessary,” said Richard J. Baron, M.D., president and CEO of the ABIM Foundation. “The content of this list and all of the others developed through this effort are helping physicians and patients across the country engage in conversations about what care they need, and what we can do to reduce waste and overuse in our health care system.”

To date, nearly 100 national and state medical specialty societies, regional health collaboratives and consumer partners have joined the conversations about appropriate care. With the release of these new lists, the campaign will have covered more than 250 tests and procedures that specialty society partners say are overused and inappropriate, and that physicians and patients should discuss.

“Discussion between the physician and the patient and patient’s family is the foundation for delivering optimal, effective care,” said SCAI 2013-14 President Ted A. Bass, M.D., FSCAI. “Clinical judgment remains critical in determining the best course of care for the individual patient, with the complementary use of guidelines and appropriate use criteria.”

The Choosing Wisely campaign reaches millions of consumers nationwide through a stable of consumer and advocacy partners, led by Consumer Reports — the world’s largest independent product-testing organization — which has worked with the ABIM Foundation to distribute patient-friendly resources for consumers and physicians to engage in these important conversations.

For more information: www.SCAI.org, www.ChoosingWisely.org

 

Related Content

Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
pregnant women, congenital heart disease, new recommendations, Circulation journal, UCLA
News | Womens Healthcare| February 16, 2017
February 16, 2017 — New recommendations for healthcare providers, published in the American Heart Association journal
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, PRO-Kinetic Energy cobalt chromium coronary stent system, FDA approval
Technology | Stents Bare Metal| February 15, 2017
The PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from Biotronik has gained U.S. Food and Drug...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | CT Angiography (CTA)| February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
Overlay Init